Table 3.

Stabilizers used for preparation of the nanoformulation.

NO	Code	D:P (mg)	Stabilizer (10 mL)	Stabilizer (%)	Size (nm)	PDI	Z.P(mv)	E. E (%)
01	PTX 01	1:10	PVA	1:0	347 ± 10.3	0.6 ± 0.01	−8.1 ± 1.8	55
02	PTX 05	1:10	Pluronic F-127	1:0	190 ± 13.2	0.2 ± 0.03	−8.1 ± 1.8	71
03	PTX 21	1:10	Poloxamer 407	1:0	249 ± 9.7	0.19 ± 0.01	−5.6 ± 0.21	83
04	PTX 124	1:10	Tween 80	1:0	261 ± 12.2	0. ± 0.04	−7.39 ± 0.1	41
05	PTX 126	1:10	Span 20	1:0	160 ± 11.9	0.9 ± 0.2	0.6 ± 1.1	25
06	PTX 131	1:10	SDS	1:0	482 ± 7.1	0.9 ± 0.01	−51.6 ± 0.1	24
07	PTX 142	1:10	SLS	1:0	203 ± 7.3	0.4 ± 0.06	−40.8 ± 1.4	56
08	PTX 66	1:10	PVAa + SLSb	1:0.05	279 ± 13.1	0.8 ± 0.04	−4.16 ± 0.11	68
09	PTX 88	1:10	Pluronic F-127a + SLSb	1:0.05	371 ± 22.61	0.7 ± 0.02	−29.77 ± 0.2	76
10	PTX 104	1:10	Poloxamer 407a + SLSb	1:0.05	199 ± 21.80	0.4 ± 0.01	−26.85 ± 0.03	77
11	PTX 120	1:10	Tween 80a + SLSb	1:0.05	198 ± 14.6	0.4 ± 0.23	−43.2 ± 1.01	41
12	PTX 133	1:10	SDSa + SLSb	1:0.05	333 ± 15.5	0.5 ± 0.05	−50.1 ± 0.21	35
13	PTX 137	1:10	Span 20a + SLSb	1:0.05	391 ± 9.7	0.9 ± 0.06	−60.2 ± 0.09	66

^a5 mL, ^b 5 mL, D: Paclitaxel, P: PLGA.